![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 31, 22095-22101, July 30, 1999
From the Johns Hopkins Oncology Center Research Laboratories,
Baltimore, Maryland 21231
The increased transcription and ultimate
superinduction of the spermidine/spermine
N1-acetyltransferase (SSAT) gene has been
associated with the antineoplastic activity of several new antitumor
polyamine analogues. In sensitive tumor cell types, the transcriptional
induction appears to be regulated by the constitutive association of
the transcription factor Nrf-2 with the recently discovered
polyamine-responsive element. Using the yeast two-hybrid system, a new
transcriptional cofactor, polyamine-modulated factor-1 (PMF-1), has
been identified as a partner protein of Nrf-2 that, in combination with
Nrf-2, regulates the polyamine analogue-induced transcription of SSAT. The human PMF-1 gene, located on chromosome 1 near the 1q12/1q21 border, yields an mRNA transcript of ~1.2 kilobases that codes for a 165-amino acid protein with a predicted molecular mass of ~20
kDa. The PMF-1 mRNA appears to increase in response to analogue exposure only in analogue-responsive cells. In addition to the transcriptional regulation of SSAT, PMF-1 or similar factors should be
considered in the regulation of other polyamine-dependent genes.
The absolute requirement for polyamines in the growth of
eukaryotic cells has led to the targeting of their metabolic pathway as
a means of antineoplastic intervention (1). Several newly synthesized
polyamine analogues designed to alter regulation of polyamine
metabolism are currently under investigation for their antitumor
activity (2-5). Some of these analogues appear to exert their
cytotoxic effects in association with the superinduction of
spermidine/spermine N1-acetyltransferase
(SSAT),1 the rate-limiting
step of polyamine catabolism (6-11). The initial induction of this
enzyme occurs at the level of increased transcription in response to
analogue treatment (12-14). We have recently identified a
cis-acting polyamine-responsive element (PRE) and a
trans-acting protein, the transcription factor Nrf-2, to be
involved in the regulation of SSAT gene transcription (14). However,
the Nrf-2 transcription factor appears to be constitutively expressed
only in those tumor cell types capable of highly expressing SSAT.
Furthermore, the binding of Nrf-2 to the PRE does not change in
response to treatment with either the analogues or the natural
polyamines as measured by electrophoretic mobility shift assays
(14).
The results of these recent studies suggest at least two possibilities:
1) PRE-bound Nrf-2 is altered by analogue treatment, leading to
transcriptional activation, or 2) an additional factor that is induced
by analogue exposure leads to transcriptional activation of the SSAT
gene. In this study, we have used the yeast two-hybrid system to
identify and clone a newly identified human protein,
polyamine-modulated factor-1 (PMF-1), that interacts with the leucine
zipper region of Nrf-2 and activates SSAT transcription. Additionally,
we demonstrate that this gene is rapidly induced in response to
analogue treatment in a polyamine analogue-sensitive lung tumor cell
line, strongly suggesting that PMF-1 mediates SSAT transcriptional
induction by acting in cooperation with Nrf-2. These results also
implicate the possibility that this or other transcriptional cofactors
are important in the response of other genes regulated by the natural
polyamines or their analogues and that PMF-1 may serve as a paradigm
for understanding the increased requirement of polyamines in the
transformed phenotype (15-18).
Chemicals and
Reagents--
N1,N11-Bis(ethyl)norspermine
(BENSpm) was kindly provided by Parke-Davis. 2-Difluoromethylornithine
was obtained as a gift from the Marion-Merrell-Dow Research Institute
(Cincinnati, OH). Radionucleotides, [ Plasmid Construction and Yeast Two-hybrid Screening--
For
construction of plasmid pCR2.1/Nrf-2, reverse transcription-PCR was
performed using the primer pair P1-P2 (see Fig. 1). A 2017-bp Nrf-2
cDNA (+27 to +2043 bp) fragment was derived from H157 mRNA. The
PCR product was then ligated into the pCR2.1 vector. To construct
plasmid pcDNA3.1/Nrf-2, the Nrf-2 cDNA fragment cut from
pCR2.1/Nrf-2 by KpnI-EcoRV was inserted into the
pcDNA3.1(
Yeast two-hybrid screening was performed with the Matchmaker two-hybrid
system. To construct the bait plasmids, the coding region of the Nrf-2
cDNA (+39 to +2043 bp) and the leucine zipper domain (+1338 to
+2043 bp) of Nrf-2 protein were produced by PCR with pCR2.1/Nrf-2 as
the template. The primers used to amplify full-length Nrf-2 (P5 and P7)
or the Nrf-2 leucine zipper domain (P6 and P7) were designed to contain
an XbaI or a SalI restriction site in the 5'-end,
respectively (see Fig. 1, underlined sequences). The PCR
products were digested with XbaI-SalI and then
subcloned in frame into the same restriction sites in the DNA-binding
domain of Gal4 in the pAS2.1 vector. To construct the pACT-2/H157
cDNA library, H157 cDNA was synthesized using the Promega
cDNA synthesis system according to the manufacturer's protocol.
The double-stranded cDNA was ligated to EcoRI adapters
on both ends and then cloned into the Gal4 transcriptional activation
domain in the pACT-2 vector, which had been digested with
EcoRI and dephosphorylated with calf intestine alkaline
phosphatase. The pACT-2/H157 cDNA library was then screened by the
"HIS3 Jump-Start" procedure according to the protocol from the manufacturer.
Saccharomyces cerevisiae Y190 cells were first transformed
with bait plasmids and selected on synthetic dextrose medium lacking tryptophan (SD Cloning PMF-1 cDNA from the Human Placental Retroviral
cDNA Library--
The P10 primer, representing the 5'-pLIB vector
sequence upstream from the multiple cloning site, and the P11 primer,
corresponding to sequence in the 3'-end of PMF-1 cDNA (997-1020
bp), were used to clone the PMF-1 cDNA from a human placental
retroviral cDNA library into the pLIB vector
(CLONTECH) by PCR. This PCR product was then
subcloned into the pCR2.1 vector (pCR2.1/PMF-1).
Human BAC Library Screening--
A human BAC library was
screened to obtain the PMF-1 genomic sequence using the PCR protocol
supplied by the manufacturer. Three pairs of primers used in the PCR
screening were designed according to PMF-1 cDNA sequence (P12-P13,
P14-P15, and P16-P17) (see Fig. 1).
P-6, the positive BAC library clone, was digested with
HindIII restriction enzyme and subcloned into the
pBluescript SK vector. The P-6 sublibrary was then screened
for the clones containing PMF-1 genomic fragments (clones A, B, and E) by the colony lift procedure and subjected to Southern blot analysis with random primer-labeled (19, 20) PMF-1 cDNA. Another three PMF-1
genomic DNA fragments (clones AB, C, and D) were obtained by PCR
techniques with the P-6 plasmid as the template. The DNA
inserts in the positive clones were sequenced on the ABI Automated DNA Sequencer.
Chromosomal Localization of PMF-1--
The radiation hybrid
screening technique with the Stanford G3 RH panel (Research Genetics)
was used to determine the chromosomal location of PMF-1 as per the
supplier's PCR protocol. The primers used for these reactions were P22
and P23 (see Fig. 1).2
Fluorescent in situ hybridization analysis was performed as
previously reported (21) using the labeled 5-kb B and 10-kb E fragments (see Fig. 4A) as probes.
In Vitro Transcription and Translation--
In vitro
transcription and translation were performed with the TnT coupled
transcription/translation lysate system using
[ RNA Isolation and Northern Blot Analysis--
Total cellular RNA
from H157 and H82 cells was extracted using the acid phenol-guanidine
isothiocyanate method (22). Poly(A+) RNA was isolated using
oligo(dT)-cellulose chromatography following the manufacturer's directions.
Ten µg of total RNA from H157 or H82 cells were separated on a
denaturing 1.5% agarose gel containing 6% formaldehyde, transferred to GeneScreen membrane (NEN Life Science Products), and hybridized with
a random primer-labeled PMF-1 cDNA as a probe. Blots were washed
and reprobed with a 28 S ribosomal cDNA probe as a loading control.
The human multiple-tissue Northern blot system was used to examine the
expression of PMF-1 in various human tissues according to the
manufacturer's protocol.
Transient Transfection Assays--
For transient transfection,
2 × 105 H157 cells were seeded in a 35-mm diameter
culture dish and cultured in RPMI 1640 medium containing 5 mM 2-difluoromethylornithine for 48 h to reduce
endogenous polyamines and background transcription, as previously
reported (14). The Lipofectin-mediated transfection was performed with 1.5 µg of luciferase reporter constructs as indicated under
"Results" and 0.4 µg of control plasmid pSV- Identification of PMF-1 as a Co-transcription Partner of
Nrf-2--
The Nrf-2 transcription factor was found to be associated
with the cell type-specific expression of SSAT in response to the antitumor polyamine analogues by binding to the newly identified PRE
(14). However, Nrf-2 was found to bind constitutively to the PRE,
strongly suggesting an association with another protein that mediates
the analogue-induced expression of SSAT. To identify proteins that can
interact with Nrf-2 in the H157 cell line, the yeast two-hybrid
screening technique was used. In initial experiments, two pAS2.1
constructs were used as bait: full-length Nrf-2 (amino acids 1-589)
and the leucine zipper domain of Nrf-2 (amino acids 434-589). Each
construct was fused to the Gal4 DNA-binding domain. However, in
testing, the full-length Nrf-2 fusion plasmid (pAS2.1/Nrf-2) strongly
activated the lacZ and HIS3 reporter genes in the
host Y190 cells in the absence of the Gal4 transcriptional activation domain (data not shown). Consequently, the bait plasmid containing only
the leucine zipper domain of Nrf-2 (pAS2.1/Nrf-2-LZ) was used for
further experimentation. An H157 cDNA library that expressed proteins fused to the Gal4 transcriptional activation domain was then
constructed and screened by the HIS3 Jump-Start procedure (see
"Experimental Procedures"). Thirty-three clones from
~106 yeast transformants were identified that could
activate the reporter genes. Inserts of the positive clones were
amplified by PCR with Matchmaker 5' (P8) and 3' (P9) (Fig.
1) binding domain insert screening
amplimers and digested with restriction enzyme AluI. Gel
electrophoresis/ethidium bromide staining results demonstrated an
identical insert of ~1 kb (data not shown), which was designated as
PMF-1. To confirm the interaction between the Nrf-2 leucine zipper
domain and PMF-1, Y190 yeast cells were transformed with pAS2.1/Nrf-2-LZ alone, pACT-2/PMF-1 alone, or pAS2.1/Nrf-2-LZ and
pACT-2/PMF-1 together. Transformants were then selected on SD
PMF-1 cDNA contains an open reading frame of 495 bp and is
predicted to encode for a protein of 165 amino acids with a calculated molecular mass of 19.2 kDa (Fig. 3). The
sequence surrounding the translational initiation codon
(5'-GACACCATGG) is a nearly perfect consensus with the Kozak
translational consensus sequence (23-25), with 9 out of 10 matches for
the proposed optimal context (5'-GCC(A/G)CCATGG). The polyadenylation
signal sequence (AATAAA) is found at nucleotide 1025, 13 bp upstream
from the poly(A) tail. A leucine zipper-like structure with
IX6IX6IX5LX6L was found in the N-terminal region and is a possible domain responsible for the protein-protein interaction between Nrf-2 and PMF-1.
Genomic Structure of PMF-1--
To obtain the PMF-1 gene, the
human BAC library was screened by PCR techniques. Screening at three
consecutive levels of the library (BAC super pool library, BAC plate
pool library, and BAC single clone library) resulted in the discovery
of a positive clone, P-6, which was used as a template for
all three primer pairs (Fig. 1). To facilitate plasmid preparation and
sequencing, the DNA insert in the P-6 clone was digested
with HindIII and subcloned into the pBluescript SK vector.
The P-6 subclone library was then screened by colony lift
assay and Southern blot analysis with the PMF-1 cDNA probe. Three
positive clones (A, B, and E) were found to contain the PMF-1 genomic
fragments. The identification of DNA sequences of clones A, B, and E
allowed for the design of new primers (Fig. 1) for cloning DNA
sequences between A and B (fragment AB) and between B and E (fragments
C and D) using the PCR technique with the P-6 plasmid as the template.
The overall length of the assembled human PMF-1 genomic sequence from
the above clones is ~28 kb. These clones span the entire cDNA
region of PMF-1 and define the five complete exons and four introns
(Fig. 4A). Clone A also
defines 11.2 kb upstream from the transcriptional start site. The
sequences in the exon/intron junctions and the sizes of the introns and
exons are shown in Table I. All of the
splice junctions in the PMF-1 gene conform to consensus sequence
established for splice donor (5'-GT(A/G)AGT-3') and splice acceptor
(5'-(Py)nN(C/T)AG-3') sites (26). Exon 1 contains 111 bp of
5'-untranslated sequence and the first 41 bp of coding sequence. Exon 5 contains the sequence coding for the last 17 amino acids of PMF-1, the
stop codon (TGA), and a 434-bp 3'-untranslated sequence of the PMF-1
cDNA.
It should be noted that extensive searching of the
GenBankTM data base indicates that the PMF-1 cDNA and
genomic sequences are unique. No previous expressed sequence tags,
cDNAs, or genomic clones of this region have been reported.
Putative Transcription Factor-binding Sites in the PMF-1 Promoter
Region--
The TESS program was used to identify putative binding
sites (Fig. 4B) for known transcription factors in the PMF-1
promoter region 2 kb immediately upstream from the transcriptional
start site.3 It should be
noted that one potential PRE-binding site (14) was identified in this
region ( Chromosomal Location of PMF-1--
The radiation hybrid screening
technique and the Stanford G3 RH panel were used to localize the human
PMF-1 gene. Primers P22 and P23, spanning from within exon 4 into
intron 4, were used, and the results indicate that the PMF-1 gene is on
the long arm of chromosome 1 at the 1q12 locus. Since this region
represents the large pericentric heterochromatin of 1q and the
resolution of the markers determined from the radiation hybrid
screening was not sufficient to precisely place PMF-1, fluorescent
in situ hybridization analysis was performed to confirm the
location of PMF-1. The results of 22 G-banded metaphase chromosome
pairs indicated PMF-1 to be at the 1q12/1q21 border (14 of 22 signals
were at the 1q12/1q21 border).
In Vitro Transcription and Translation of PMF-1
cDNA--
In vitro transcription and translation of
full-length PMF-1 cDNA produced a major band with an apparent
molecular mass of ~20 kDa, which agrees with the predicted open
reading frame (Fig. 5).
Expression of PMF-1 mRNA in Human Tissues--
The expression
of PMF-1 mRNA in a variety of normal human tissues was evaluated by
Northern blot analyses. A 1.2-kb mRNA transcript of PMF-1 was
observed and appears to be expressed almost ubiquitously, although at
different levels, in multiple tissues. The heart and skeletal muscle
were among the highest in PMF-1 expression, with significant levels
expressed in the kidney and liver (Fig.
6).
Expression of PMF-1 in Response to Polyamine Analogue Exposure in
Human Lung Cancer Cells--
To determine if PMF-1 expression can be
induced by treatment with the polyamine analogue BENSpm in a cell
type-specific manner, total RNA from the analogue-sensitive H157 and
analogue-insensitive H82 cells was analyzed by Northern blot analysis
after a 24-h exposure to 10 µM BENSpm. Significant
induction of PMF-1 mRNA was detected only in the polyamine
analogue-sensitive cell line, H157 (Fig.
7). To further characterize the
expression of PMF-1 in H157 cells, a time course analysis of BENSpm
exposure was performed. PMF-1 was induced in a biphasic manner, peaking
first at ~4 h post-treatment and reaching levels >5-fold after a
24-h exposure to BENSpm (Fig. 8). It
should be noted that longer treatment times of H157 cells with BENSpm
are precluded since there is significant drug-induced toxicity between
12 and 24 h of exposure (3, 27). It is also important to note
that, although the biphasic nature of PMF-1 expression was reproducible
in several experiments, the biological significance of this observation
is not currently known. Once a PMF-1 antibody is developed, definitive
experiments will be performed to determine whether the biphasic nature
of message expression is mirrored by protein expression.
Functional Analysis of PMF-1 by Transient Transfection of H157
Cells--
To determine whether PMF-1 could induce PRE-mediated
transcription of the SSAT promoter, two reporter plasmids were
constructed. One plasmid, pBKH-93, contains the minimal promoter region
of the SSAT gene ( The superinduction of the rate-limiting step in polyamine
catabolism, SSAT, has been implicated in the cytotoxic response of some
tumor types to treatment with antineoplastic polyamine analogues (6, 9,
29). Although regulated at many levels, the first and necessary step is
a modest increase in transcription (12, 30). The recently discovered
PRE and associated Nrf-2 transcription factor necessary for the
transcriptional induction of SSAT provided an excellent lead for
defining other proteins required in the transcriptional regulation of
SSAT. That Nrf-2 was found to be constitutively bound to the PRE in
sensitive cell types even in the absence of treatment suggested that
other factors were involved in the induction response (14). In this
work, a transcriptional cofactor has been identified using the yeast two-hybrid system. This factor, designated PMF-1, binds to the leucine
zipper region of Nrf-2, resulting in increased transcription.
More important, PMF-1 demonstrates a cell type-specific response to
analogue exposure. Specifically, PMF-1 appears to be induced only in
the analogue-responsive cell types. Furthermore, using a luciferase
reporter construct system, PMF-1 is capable of inducing PRE-regulated
transcription, even in the absence of analogue. These results are
consistent with the hypothesis that Nrf-2 is constitutively expressed
in H157 cells and that an increase in PMF-1, either as a result of
analogue treatment or by direct transfection, is capable of increasing
PRE-mediated transcription in human cells. However, it is currently not
known whether preexisting PMF-1 protein is important in the activation
of SSAT expression or if newly synthesized protein is required. These
experiments will require the development of an antibody against the new
PMF-1 protein.
Although it is apparent from the yeast two-hybrid system results that
PMF-1 binds to the leucine zipper region of Nrf-2, it is not currently
known what region of PMF-1 interacts with the leucine zipper. Primary
structure analysis of PMF-1 demonstrates an amino acid stretch in the
N-terminal region that resembles a leucine zipper motif. Mutation
analysis of the N-terminal region will be required to determine whether
it is specifically involved in heterodimer formation with Nrf-2. It is
important to note that previous studies have demonstrated that Nrf-2
activates transcription when heterodimerized with a member of the small
Maf protein family (31). PMF-1 has no amino acid homology to any of the
known Maf family members; therefore, PMF-1 appears to be a structurally unique partner of Nrf-2.
Although PMF-1 clearly plays a role in the transcriptional regulation
of SSAT, it is possible that it may be responsible for the regulation
of other genes, in combination with either Nrf-2 or other potential
partners. It may be significant that the highest expression of PMF-1 in
normal tissues occurs in tissues that are highly differentiated,
including heart, skeletal muscle, kidney, and liver. The possibility
that PMF-1 expression is involved in differentiation or is inversely
proportional to growth cannot presently be excluded. Again, it is
important to emphasize that the relative amounts of PMF-1 protein may
be critically important in determining its role in transcriptional
regulation for both SSAT and other potential gene targets in response
to various stimuli. However, the performance of studies to investigate
PMF-1 protein levels and roles will require the development of a
PMF-1-specific antibody.
It has been demonstrated that c-Myc transcription is negatively
regulated by polyamine depletion in several tumor types along with
other growth-related genes (32-35). Recently, it has been demonstrated that the depletion of polyamines by
2-difluoromethylornithine or the alteration of polyamine metabolism
through the use of analogues leads to cell cycle arrest and can induce
apoptosis through a p53-mediated mechanism (36, 37). Since polyamines
and polyamine biosynthetic enzyme activities are typically higher in
tumors than in surrounding normal tissue (38-41), the resulting higher polyamine content may play a role in the regulation of genes associated with the neoplastic phenotype. Recent studies using the overexpression of ornithine decarboxylase as a means of determining the transformation potential of increased polyamine biosynthesis suggest that the expression of both growth-related and transformation-related genes may
have an altered requirement for polyamines (15-18, 28, 41-42). These
genes may in turn be modulated by PMF-1 or similar transcriptional cofactors. The search for other transcription factors whose activity is
modulated by PMF-1 is underway.
*
This work was supported by National Institutes of Health
Grants CA51085 and CA58184.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF141308, AF141309, and AF141310.
2
Analysis of results was performed using the
protocol at the Stanford web site.
3
TESS can be found at the following URL:
http://dot.imgen.bcm.tmc.edu:9331/ under "Gene Features Search."
The abbreviations used are:
SSAT, spermidine/spermine N1-acetyltransferase;
PRE, polyamine-responsive element;
PMF-1, polyamine-modulated factor-1;
BENSpm, N1,N11-bis(ethyl)norspermine;
BAC, bacterial artificial chromosomal;
PCR, polymerase chain reaction;
bp, base pair(s);
kb, kilobase(s).
Cloning and Characterization of Human Polyamine-modulated
Factor-1, a Transcriptional Cofactor That Regulates the Transcription
of the Spermidine/Spermine
N1-Acetyltransferase Gene*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP, and
[
-35S]methionine were supplied by Amersham Pharmacia
Biotech. A human placental retroviral cDNA library, the Matchmaker
yeast two-hybrid system, yeast culture media, and a human
multiple-tissue Northern blot system were purchased from
CLONTECH (Palo Alto, CA). A human bacterial
artificial chromosomal (BAC) DNA library was obtained from Research
Genetics (Huntsville, AL). Lipofectin reagent was purchased from Life
Technologies, Inc. The luciferase assay system, TnT coupled
transcription/translation reticulocyte lysate systems, and the cDNA
synthesis system were purchased from Promega (Madison, WI), and the
Gal-XE chemiluminescent reporter gene assay system was purchased from
ICN Pharmaceuticals (Cosa Mesa, CA). Restriction and DNA-modifying
enzymes were purchased from Life Technologies, Inc., New England
Biolabs Inc. (Beverly, MA), and Sigma. Oligo(dT)-cellulose was
purchased from Roche Molecular Biochemicals. The TA cloning kit was
purchased from Invitrogen (Carlsbad, CA). All oligonucleotides used in
the experiments were synthesized by Life Technologies, Inc. Other
chemicals were purchased from Sigma, Roche Molecular Biochemicals and
J. T. Baker Inc.
) vector digested with the same enzymes. To construct
plasmid pcDNA3.1/PMF-1, the PMF-1 cDNA was cut from
pCR2.1/PMF-1 with EcoRI-XhoI and cloned into the
pcDNA3.1(+) vector digested with the same restriction enzymes. The
pBKH-93 plasmid was constructed as previously reported (14). To make
pBKH-93/dPRE, the complementary oligonucleotides P3 and P4 (see Fig. 1)
were annealed, and the protruding ends were filled with Taq
DNA polymerase. The resulting 30-bp double-stranded DNA fragment
containing two PRE elements in the same direction (GACCGCTATGACTAAGCG TATGACTAAGCG) was cloned
into the pCR2.1 vector. The PRE-containing fragment was then excised by
KpnI-XhoI digestion and inserted into pBKH-93 in
the same restriction sites.
Trp). The transformants grown on the SD
Trp medium were subsequently transformed with the pACT-2/H157 cDNA library and
selected on medium lacking tryptophan and leucine (SDTMrp
Leu). The clones co-transformed with the bait and library were collected and
replated onto medium lacking tryptophan, leucine, and histidine (SD
Trp
Leu
His) with 30 mM 3-amino-1,2,4-triazole to
inhibit the leaking growth of Y190 cells. The clones selected in this step were further assayed for their
-galactosidase activity. The
pACT-2 library plasmids were purified from individual positive clones
and amplified in Escherichia coli. Sequencing of the
cDNA insert in the positive clone was performed with a Perkin-Elmer ABI Automated DNA Sequencer.
-35S]methionine according to the manufacturer's
protocol. Purified plasmid pcDNA3.1/PMF-1 was used as the template.
The labeled translation products were separated by 15%
SDS-polyacrylamide gel electrophoresis and exposed to Kodak X-Omat film.
-galactosidase
according to the manufacturer's protocol. After a 5-h incubation, the
DNA-Lipofectin complex-containing medium was replaced by RPMI 1640 medium containing 5 mM 2-difluoromethylornithine.
Forty-eight h after transfection, the cells were exposed to 10 µM BENSpm for 2 h. The cells were harvested,
quick-frozen, and subsequently prepared for luciferase activity
measurements as per the instructions of the manufacturer. To account
for variations in transfection efficiency, the luciferase activity was
normalized to the
-galactosidase activity.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
His
Leu
Trp medium containing 30 mM
3-amino-1,2,4-triazole. Only clones co-transformed with pAS2.1/Nrf-2-LZ
and pACT-2/PMF-1 grew on the selection medium, demonstrating
transcriptional activation of the reporter gene (Fig.
2). Sequencing the insert in the positive clone (pACT-2/PMF-1) revealed a 958-bp cDNA that coded a novel Nrf-2 partner. To confirm the PMF-1 sequence, the cDNA was
PCR-cloned using the retroviral cDNA library derived from human
placenta. Using this method, a transcript of 1057 bp was identified.
This clone contains 99 more bases in the 5'-end as compared with the cDNA obtained from the yeast two-hybrid assay. This message size correlates well with the mRNA length estimated by Northern blotting (see below).

View larger version (53K):
[in a new window]
Fig. 1.
Primers and oligomers used as indicated under
"Experimental Procedures."

View larger version (46K):
[in a new window]
Fig. 2.
Protein-protein interaction between
Nrf2 and PMF-1 demonstrated in the yeast two-hybrid
analysis. S. cerevisiae Y190 cells were transformed
with pAS2.1/Nrf-2-LZ alone or pACT-2/PMF-1 alone or co-transformed with
pAS2.1/Nrf-2-LZ and pACT-2/PMF-1. The transformants were then selected
on SD
Trp
Leu
His medium with 30 mM
3-amino-1,2,4-triazole. Only co-transformed clones could grow on the
selection medium, indicating the required interaction for
transcriptional activation.

View larger version (59K):
[in a new window]
Fig. 3.
Nucleotide and predicted amino acid sequences
of the human PMF-1 cDNA. The ATG initiation codon,
the TGA stop codon, and the AATAAA
polyadenylation signal are in boldface. The Kozak
translational consensus sequence is underlined.

View larger version (42K):
[in a new window]
Fig. 4.
Genomic structure of the human PMF-1
gene. A, the five exons are numbered and represented by
filled boxes. The size of intron 1 is approximate. The
fragments at the top indicate the positions of positive clones that
contain PMF-1 genomic sequences (A, AB, B, C, D, and E). B,
shown is the upstream promoter region of PMF-1. Two kb of the upstream
promoter region with putative transcription factor-binding sites are as
indicated. Only known transcription factors with a TESS quality score
of 0.850 and higher are included. Note that an 8 out of 9-bp match to
the PRE is located in the antisense orientation between
1450 and
1442 relative to the transcriptional start site.
Exon/intron organization of the human PMF-1 gene
1450 to
1442 bp). This site has 8 out of 9 base pairs
identical to the previously described PRE (14) and oriented in the
antisense direction. Although several putative transcription
factor-binding sites have been identified, further experimentation will
be necessary to determine whether any of the identified sites have any
actual function. It should be noted that, similar to SSAT (21), the
transcription of PMF-1 is driven by a TATA-less promoter.

View larger version (46K):
[in a new window]
Fig. 5.
In vitro transcription and
translation of human PMF-1. The assay was performed in the
presence of [35S]methionine with 2 µg of plasmid as
template in a 50-µl TnT reaction. The labeled translation products
were then separated by 15% SDS-polyacrylamide gel electrophoresis. The
templates used in the assays were pcDNA3.1/PMF-1 (lane
A) and the pcDNA3.1 vector (lane B). The
arrow indicates the position of PMF-1 protein.

View larger version (38K):
[in a new window]
Fig. 6.
Expression of PMF-1 in normal human
tissues. The expression of PMF-1 mRNA was evaluated by
Northern blot analysis using mRNA derived from 12 normal human
tissues. Random primer-labeled PMF-1 cDNA was used as a
hybridization probe. The arrow indicates the position of
PMF-1 mRNA.

View larger version (27K):
[in a new window]
Fig. 7.
Induction of PMF-1 expression by BENSpm in
H157 cells. A, 10 µg of total cellular RNA were used
in each lane for Northern blot analysis with labeled PMF-1 cDNA as
a probe. Lane 1, H157 control cells; lane
2, H157 cells treated with 10 µM BENSpm for
24 h; lane 3, H82 control cells;
lane 4, H82 cells treated with 10 µM BENSpm for 24 h. B, the blot was
boiled and reprobed with labeled human 28 S ribosomal DNA.

View larger version (9K):
[in a new window]
Fig. 8.
Time course of PMF-1 induction by BENSpm in
H157 cells. H157 cells were treated with 10 µM
BENSpm for 0-24 h. Total cellular RNA was prepared, and 10-µg
samples were subjected to sequential Northern blot analyses with
labeled PMF-1 cDNA and 28 S ribosomal cDNA as a loading
control. Results are expressed as a ratio of PMF-1 to 28 S ribosomal
RNA. The data in this figure are from a single experiment
representative of three individual experiments with comparable
results.
93 to
1 bp) upstream from the luciferase gene. The second plasmid, pBKH-93/dPRE, contains the minimal promoter region
and a 30-bp oligonucleotide containing two PRE consensus sequences (14)
(TATGACTAA) cloned into a site upstream from the minimal SSAT promoter
in pBKH-93. For expression of Nrf-2 and PMF-1, the cDNAs of Nrf-2
and PMF-1 were cloned into the pcDNA3.1 vector. A PRE-mediated
induction of luciferase expression in the BENSpm-treated H157 cell line
was demonstrated in the transient transfection assay using the
PRE-containing construct pBKH-93/dPRE. Transfection of the reporter
construct together with pcDNA3.1/PMF-1 (no addition of BENSpm)
produced an increase in transcription that is comparable to the
increase in luciferase activity observed after the addition of BENSpm
without co-transfection with pcDNA3.1/PMF-1. Additional expression
of Nrf-2 in the presence or absence of PMF-1 had little effect on the
reporter construct expression (Fig. 9). These results demonstrate that PMF-1, not Nrf-2, is the limiting factor
in this system and that an increase in PMF-1 in the presence or absence
of the analogue can lead to a PRE-mediated increase in
transcription.

View larger version (30K):
[in a new window]
Fig. 9.
Involvement of PMF-1 in PRE-mediated
transcriptional activation. H157 cells were pretreated for 48 h with 5 mM 2-difluoromethylornithine and co-transfected
with control plasmid (pSV-
-galactosidase (pSV-
-gal))
and the indicated reporter constructs. A, effects of PMF-1
on PRE-mediated luciferase expression; B, constructs used in
the co-transfection. It is important to note that the expression of
PMF-1 alone, even in the absence of analogue, leads to a significant
increase in luciferase activity (Conditions F). It should
also be noted that pGL-2 Basic refers to a promoterless construct and
that the pg.-2 Control refers to a construct containing the SV40 viral
promoter.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
To whom correspondence should be addressed: Johns Hopkins
Oncology Center Research Labs., 424 North Bond St., Baltimore,
MD 21231. Tel.: 410-955-8580; Fax: 410-614-9884; E-mail:
casero@welchlink.welch.jhu.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Marton, L. J.,
and Pegg, A. E.
(1995)
Annu. Rev. Pharmacol.
35,
55-91[CrossRef][Medline]
[Order article via Infotrieve]
2.
Saab, N. H.,
West, E. E.,
Bieszk, N. C.,
Preuss, C. V.,
Mank, A. R.,
Casero, R. A.,
and Woster, P. M.
(1993)
J. Med. Chem.
36,
2998-3004[CrossRef][Medline]
[Order article via Infotrieve]
3.
Casero, R. A.,
Mank, A. R.,
Saab, N. H.,
Wu, R.,
Dyer, W. J.,
and Woster, P. M.
(1995)
Cancer Chemother. Pharmacol.
36,
69-74[Medline]
[Order article via Infotrieve]
4.
Bernacki, R. J.,
Oberman, E. J.,
Seweryniak, K. E.,
Atwood, A.,
Bergeron, R. J.,
and Porter, C. W.
(1995)
Clin. Cancer Res.
1,
847-857[Abstract]
5.
Bergeron, R. J.,
Feng, Y.,
Weimar, W. R.,
McManis, J. S.,
Dimova, H.,
Porter, C.,
Raisler, B.,
and Phanstiel, O.
(1997)
J. Med. Chem.
40,
1475-1494[CrossRef][Medline]
[Order article via Infotrieve]
6.
Casero, R. A.,
Celano, P.,
Ervin, S. J.,
Porter, C. W.,
Bergeron, R. J.,
and Libby, P. R.
(1989)
Cancer Res.
49,
3829-3833 7.
Casero, R. A.,
Mank, A. R.,
Xiao, L.,
Smith, J.,
Bergeron, R. J.,
and Celano, P.
(1992)
Cancer Res.
52,
5359-5363 8.
Alhonen, L.,
Karppinen, A.,
Uusi-Oukari, M.,
Vujcic, S.,
Korhonen, V.-P.,
Halmekyto, M.,
Kramer, D. L.,
Hines, R.,
Janne, J.,
and Porter, C. W.
(1998)
J. Biol. Chem.
273,
1964-1969 9.
Porter, C. W.,
Ganis, B.,
Libby, P. R.,
and Bergeron, R. J.
(1991)
Cancer Res.
51,
3715-3720 10.
Porter, C. W.,
Bernacki, R. J.,
Miller, J.,
and Bergeron, R. J.
(1993)
Cancer Res.
53,
581-586 11.
Ha, H. C.,
Woster, P. M.,
Yager, J. D.,
and Casero, R. A., Jr.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11557-11562 12.
Fogel-Petrovic, M.,
Shappell, N. W.,
Bergeron, R. J.,
and Porter, C. W.
(1993)
J. Biol. Chem.
268,
19118-19125 13.
Xiao, L.,
and Casero, R. A.
(1996)
Biochem. J.
313,
691-696
14.
Wang, Y.,
Xiao, L.,
Thiagalingam, A.,
Nelkin, B. D.,
and Casero, R. A., Jr.
(1998)
J. Biol. Chem.
273,
34623-34630 15.
Smith, M. K.,
Trempus, C. S.,
and Gilmour, S. K.
(1998)
Carcinogenesis (Lond.)
19,
1409-1415 16.
Peralta, S. A.,
Gilliard, G.,
Megosh, L.,
George, K.,
and O'Brien, T. G.
(1998)
Cancer Res.
58,
1654-1659 17.
Auvinen, M.,
Laine, A.,
Paasinen-Sohns, A.,
Kangas, A.,
Kangas, L.,
Saksela, O.,
Andersson, L. C.,
and Holtta, E.
(1997)
Cancer Res.
57,
3016-3025 18.
Paasinen-Sohns, A.,
and Holtta, E.
(1997)
Oncogene
15,
1953-1966[CrossRef][Medline]
[Order article via Infotrieve]
19.
Southern, E. M.
(1975)
J. Mol. Biol.
98,
503-517[CrossRef][Medline]
[Order article via Infotrieve]
20.
Feinberg, A. P.,
and Vogelstein, B.
(1984)
Anal. Biochem.
137,
266-267[CrossRef][Medline]
[Order article via Infotrieve]
21.
Xiao, L.,
Celano, P.,
Mank, A. R.,
Griffin, C.,
Jabs, E. W.,
Hawkins, A. L.,
and Casero, R. A.
(1992)
Biochem. Biophys. Res. Commun.
187,
1493-1502[CrossRef][Medline]
[Order article via Infotrieve]
22.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
23.
Kozak, M.
(1989)
J. Cell. Physiol.
108,
229-241[CrossRef]
24.
Kozak, M.
(1991)
J. Cell. Physiol.
115,
887-903
25.
Kozak, M.
(1991)
J. Biol. Chem.
266,
19867-19870 26.
Mount, S. M.
(1982)
Nucleic Acids Res.
10,
459-472 27.
McCloskey, D. E.,
Yang, J.,
Woster, P. M.,
Davidson, N. E.,
and Casero, R. A., Jr.
(1996)
Clin. Cancer Res.
2,
441-446[Abstract]
28.
Shantz, L. M.,
and Pegg, A. E.
(1998)
Cancer Res.
58,
2748-2753 29.
Scemama, J.-L.,
Grabie, V.,
and Seidel, E. R.
(1993)
Am. J. Physiol.
265,
G851-G856 30.
Rucksdeschel, J. C.,
Finkelstein, D. M.,
Ettinger, D. S.,
Leech, R. H.,
Mason, B. A.,
Joss, R. A.,
and Vogl, S.
(1986)
J. Clin. Oncol.
4,
14-22[Abstract]
31.
Itoh, K.,
Chiba, T.,
Takahashi, S.,
Ishii, T.,
Igarashi, K.,
Katoh, Y.,
Oyake, T.,
Hayashi, N.,
Satoh, K.,
Hatayama, I.,
Yamamoto, M.,
and Nabeshima, Y.
(1997)
Biochem. Biophys. Res. Commun.
236,
313-322[CrossRef][Medline]
[Order article via Infotrieve]
32.
Celano, P.,
Baylin, S. B.,
and Casero, R. A., Jr.
(1989)
J. Biol. Chem.
264,
8922-8927 33.
Patel, A. R.,
and Wang, J. Y.
(1997)
Am. J. Physiol.
273,
C1020-C1029 34.
Bryans, M.,
Harley, E.,
and Gilmour, S. K.
(1996)
Biochem. Biophys. Res. Commun.
226,
618-625[CrossRef][Medline]
[Order article via Infotrieve]
35.
Tabib, A.,
and Bachrach, U.
(1994)
Biochem. Biophys. Res. Commun.
202,
720-727[CrossRef][Medline]
[Order article via Infotrieve]
36.
Ray, R. M.,
Zimmerman, B. J.,
McCormack, S. A.,
Patel, T. B.,
and Johnson, L. R.
(1999)
Am. Phys. Soc.
276,
C684-C691
37.
Kramer, D. L.,
Vujcic, S.,
Diegelman, P.,
Alderfer, J.,
Miller, J. T.,
Black, J. D.,
Bergeron, R. J.,
and Porter, C. W.
(1999)
Cancer Res.
59,
1278-1286 38.
Luk, G. D.,
and Baylin, S. B.
(1984)
N. Engl. J. Med.
311,
80-83[Abstract]
39.
Giardiello, F. M.,
Hamilton, S. R.,
Hylind, L. M.,
Yang, V. W.,
Tamez, P.,
and Casero, R. A., Jr.
(1997)
Cancer Res.
57,
199-201 40.
Marton, L. J.,
and Pegg, A. E.
(1995)
Annu. Rev. Pharmacol.
35,
55-91
41.
Tabib, A.,
and Bachrach, U.
(1998)
Int. J. Biochem. Cell Biol.
30,
135-146[CrossRef][Medline]
[Order article via Infotrieve]
42.
Kubota, S.,
Kiyosawa, H.,
Nomura, Y.,
Yamada, T.,
and Seyama, Y.
(1997)
J. Natl. Cancer Inst.
89,
567-571
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. E. Pegg Spermidine/spermine-N1-acetyltransferase: a key metabolic regulator Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E995 - E1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Tjabringa, P. S. Vezeridis, B. Zandieh-Doulabi, M. N. Helder, P. I.J.M. Wuisman, and J. Klein-Nulend Polyamines Modulate Nitric Oxide Production and Cox-2 Gene Expression in Response to Mechanical Loading in Human Adipose Tissue-Derived Mesenchymal Stem Cells Stem Cells, October 1, 2006; 24(10): 2262 - 2269. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Babbar, A. Hacker, Y. Huang, and R. A. Casero Jr. Tumor Necrosis Factor {alpha} Induces Spermidine/Spermine N1-Acetyltransferase through Nuclear Factor {kappa}Bin Non-small Cell Lung Cancer Cells J. Biol. Chem., August 25, 2006; 281(34): 24182 - 24192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Hyvonen, A. Uimari, T. A. Keinanen, S. Heikkinen, R. Pellinen, T. Wahlfors, A. Korhonen, A. Narvanen, J. Wahlfors, L. Alhonen, et al. Polyamine-regulated unproductive splicing and translation of spermidine/spermine N1-acetyltransferase RNA, August 1, 2006; 12(8): 1569 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang and R. A. Casero Jr. Mammalian Polyamine Catabolism: A Therapeutic Target, a Pathological Problem, or Both? J. Biochem., January 1, 2006; 139(1): 17 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lindemose, P. E. Nielsen, and N. E. Mollegaard Polyamines preferentially interact with bent adenine tracts in double-stranded DNA Nucleic Acids Res., March 23, 2005; 33(6): 1790 - 1803. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Choi, E. W. Gerner, L. Ramdas, J. Dupart, J. Carew, L. Proctor, P. Huang, W. Zhang, and S. R. Hamilton Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells J. Biol. Chem., February 4, 2005; 280(5): 3295 - 3304. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Babbar, N. A. Ignatenko, R. A. Casero Jr., and E. W. Gerner Cyclooxygenase-independent Induction of Apoptosis by Sulindac Sulfone Is Mediated by Polyamines in Colon Cancer J. Biol. Chem., November 28, 2003; 278(48): 47762 - 47775. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fontanier-Razzaq, D. N. Harries, S. M. Hay, and W. D. Rees Amino Acid Deficiency Up-regulates Specific mRNAs in Murine Embryonic Cells J. Nutr., August 1, 2002; 132(8): 2137 - 2142. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||